Page 3 - புற்றுநோயியல் சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
AngioSoma, Inc Is Pleased To Welcome Steven F Penderghast To Its Board Of Directors
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Dignitana expands agreement with GenesisCare to include United States
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
February 11, 2021 Molecular Templates has entered into a worldwide strategic research collaboration with Bristol Myers Squibb (BMS) to discover and develop multiple novel oncology therapies utilizing Molecular s engineered toxin body platform.
Engineered toxin bodies are a new class of targeted therapeutics that act through differentiated mechanisms of action and have the ability to force receptor internalization, deliver therapeutic payloads, and directly kill targeted cells through enzymatic inactivation of ribosomes.
Under the agreement, Molecular Templates will conduct research activities for the discovery of next-generation engineered toxin bodies for multiple targets, of which the first has been selected by BMS. BMS will have the option to obtain an exclusive worldwide license to develop and commercialize engineered toxin bodies directed to each selected target.